{"createdAt":"8/2/2020, 2:37:05 PM","timestamp":1596393425751,"Company ID number":"646","DMX_ISSUER_NAME":"TASLY PHARMACEUTICAL GROUP CO.,LTD.","DMX_ISSUER_ID":"IID000000002143133","Country of Classification":"CHINA","name":"Tasly Pharmaceutical Group Co Ltd ","code":"600535","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"天士力医药集团股份有限公司_闫凯境","group":"board","name":"闫凯境","title":"董事长,董事","isMale":true,"age":"41","degree":"博士","salary":"315.1万","stockAmount":"-","description":"闫凯境先生:1979年出生,中国国籍,无永久境外居留权,博士研究生学历。2012年4月至今,历任天士力医药集团股份有限公司董事、总经理、董事长,天士力控股集团有限公司董事、副总裁,华金(天津)投资管理有限公司董事长等,兼任中华全国工商业联合会第十二届执行委员会常委,接力中国青年精英协会理事长,天津市青年商会会长等;2009年3月至今,任国台集团及其前身董事。现任国台集团董事、发行人董事、国台怀酒董事等职务。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_蒋晓萌","group":"board","name":"蒋晓萌","title":"副董事长,董事","isMale":true,"age":"56","degree":"硕士","salary":"0.00","stockAmount":"-","description":"蒋晓萌先生,1964年11月出生,工商管理/工程学硕士,教授级高级工程师,执业药师,享受国务院特殊津贴专家,浙江省有突出贡献中青年专家,1980年12月参加工作,先后任金华市水泥厂车间主任,浙江尖峰集团股份有限公司企管部经理,浙江尖峰通信电缆有限公司总经理,浙江尖峰药业有限公司总经理,浙江尖峰集团股份有限公司副总经理、总经理。现任浙江尖峰集团股份有限公司董事长、党委书记,兼任:天士力控股集团有限公司董事局副主席、天士力医药集团股份有限公司副董事长、南方水泥有限公司董事、浙江金华南方尖峰水泥有限公司董事长、金华市通济国有资产投资有限公司董事、浙江省建材工业协会会长、浙江省商会副会长、浙江省企业家协会副会长、浙江省医药行业协会副会长、金华市企业家协会名誉会长、金华市工商业联合会主席、金华市总商会会长。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_孙鹤","group":"board","name":"孙鹤","title":"副董事长,董事","isMale":true,"age":"61","degree":"","salary":"210.1万","stockAmount":"-","description":"孙鹤先生:1959年9月出生,美藉华人,教授、博士生导师,药物研发与管理专家,临床药理学和生物药学专家。曾任美国食品药品监督管理总局(FDA)定量药理学首席科学家和主审评审官。现任天士力控股集团有限公司董事、副总裁、科技创新事业群首席执行官,天士力北美药业有限公司总经理,天津雅昂医药国际化发展促进有限公司总经理。中医药世界联盟秘书长,国家首批“千人计划”国家特聘专家、评审委员,国家教育部“2011计划”评审专家,国家重大创新专项总体专家组委员,国家中医药标准化专家技术委员会委员。兼任天津大学药学院教授、博导兼药事管理学系主任,中国科学院上海生命研究院特聘教授,天津国际医药联合研究院专家指导委员会委员,英国诺丁汉大学医学院特聘教授等职务。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_朱永宏","group":"board","name":"朱永宏","title":"董事","isMale":true,"age":"55","degree":"博士","salary":"284.7万","stockAmount":"-","description":"朱永宏先生:1965年1月出生,博士、工商管理硕士,研究员,注册执业药师,国务院特殊津贴专家。曾任天津天士力制药集团有限公司市场营销部部长,天津天士力集团有限公司总裁助理兼天士力广告有限公司总经理,天津天士力集团有限公司总裁特别助理兼天津天士力国际公司总经理,天津天士力集团有限公司董事长助理兼研究院副院长,天士力控股集团有限公司副总裁兼生产制造事业群首席执行官。现任天士力制药集团股份有限公司副董事长、总经理,兼任中国医药创新促进会副秘书长、天津滨海高新技术产业开发区科学技术协会副会长、天津市人民对外友好协会理事、天津市北辰区工商业联合会副主席等职务。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_吴迺峰","group":"board","name":"吴迺峰","title":"董事","isMale":false,"age":"68","degree":"博士","salary":"0.00","stockAmount":"91.91万","description":"吴迺峰女士:1952年出生,中国国籍,无永久境外居留权,博士研究生学历,主任药师,国务院特殊津贴专家,第十一届、十二届、十三届天津市政协委员,中国女企业家协会特邀副会长,天津市女企业家协会会长,中国企业联合会、中国企业家协会、天津慈善协会副会长,中国中西医结合学会第七届理事会、天津市红十字会第七届理事会理事,中国医师协会常务理事。1985年7月至1990年9月,任北京军区266医院主管药师;1990年10月至1994年5月,任北京军区254医院药剂科主任药师;1994年6月至1998年4月,任天津市天使力联合制药公司市场总监、总工程师;1998年5月至2000年1月,任天士力制药集团有限公司党委常委、副总裁;2000年2月至今,历任天士力控股集团有限公司及其前身党委常委、党委副书记、副总裁、总裁等,天士力医药集团股份有限公司董事;2008年1月至2019年2月,历任国台酒业有限及其前身董事,国台集团及其前身董事等。现任国台集团董事、发行人副董事长、国台怀酒董事等职务。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_苏晶","group":"board","name":"苏晶","title":"董事","isMale":true,"age":"57","degree":"本科","salary":"157.7万","stockAmount":"-","description":"苏晶:1963年02月出生,中山医科大学毕业,本科学历。1987年至1992年任北京协和医院基本外科医生,1993年至1994年任默华(中国)有限公司北区心血管销售经理,1994年至2002年任杭州默沙东(中国)有限公司北区销售推广经理,2003年至2016年先后任天士力医药营销集团市场策划部经理、处方药分公司北中国区总经理、北京分公司总经理、市场策划板块总经理、天津天士力医药营销集团有限公司轮值总经理,2016年至今任天津天士力医药商业有限公司总经理,任天津天士力医药营销集团股份有限公司董事,兼任天士力医药集团股份有限公司副总经理。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_郭云沛","group":"board","name":"郭云沛","title":"独立董事","isMale":true,"age":"73","degree":"大专","salary":"20.00万","stockAmount":"-","description":"郭云沛,1947年7月出生,中国国籍,无境外永久居留权,大专学历,高级编辑。曾担任中国医药报社副总编辑以及报社第一负责人、北京卓信医学传媒集团执行总裁、中国医药企业管理协会副会长、会长。2008年至今,任中国医药企业管理协会名誉会长、专家委员会执行主任。2015年11月至今,任北京玉德未来控股有限公司董事。2016年6月至今,兼任公司董事。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_田昆如","group":"board","name":"田昆如","title":"独立董事","isMale":true,"age":"54","degree":"博士","salary":"20.00万","stockAmount":"-","description":"田昆如,男,1966年4月生,中国国籍,无境外永久居留权。管理学博士(会计学方向),现任天津财经大学商学院会计学教授、博士生导师、天津汽车模具股份有限公司独立董事。曾任河北威远生物化工股份有限公司(600803)、天津滨海能源发展股份有限公司(000695)、天津广宇发展股份有限公司(000537)独立董事。现兼任中国商业会计学会常务理事,中国商业会计学会副会长,天津市会计学会理事。乐凯胶片(600135)天士力(600535)、力生制药(002393)、鼎信通讯(603421)独立董事。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_刘昕","group":"board","name":"刘昕","title":"独立董事","isMale":false,"age":"52","degree":"硕士","salary":"20.00万","stockAmount":"-","description":"Xin Liu(刘昕)女士:1968年2月23日出生,拥有德国科隆大学的分子生物学学士及硕士学位并兼修工商管理学。获得弗里德里希-瑙曼基金会奖学金,并在德国诺贝尔奖获得者MaxDelbruck建立的遗传研究所里完成了毕业论文的研究。曾任葛兰素史克公司伦敦总部(GSK,London)亚太地区及新兴市场的企业发展与并购的主管,曾任职于位于瑞士巴塞尔的罗氏制药总部(Roche,Basel),致力于公司全球新药业务发展,以及礼来制药公司中的并购,业务发展,和市场/销售的领导职责。现任GreaterPacificCapital(GPC)中国分公司董事总经理,GPC是一家专注于医疗健康和IT位于伦敦的私募投资公司。并兼任中美爱美津制药公司董事。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_叶正良","group":"supervisoryCommittee","name":"叶正良","title":"监事会主席","isMale":true,"age":"53","degree":"博士","salary":"0.00","stockAmount":"-","description":"叶正良先生:1967年9月出生,药学博士,工商管理硕士,研究员,国务院特贴专家。曾任中国人民解放军第254医院药师、天津天士力集团有限公司中药所所长、天津天士力集团有限公司研究院副院长、天津天士力之骄药业有限公司总经理、天士力医药集团股份有限公司常务副总经理。现任天士力医药集团股份有限公司监事会副主席、天士力控股集团有限公司副总裁、生产制造事业群首席执行官。兼任第十一届药典委员会委员、中国药学会中药和天然药物专业委员会委员、中国药学会中药资源专业委员会委员、中国药学会药物检测质量管理委员会委员、中华中医药学会中药制药工程分会副主任委员、《中国中药杂志》等杂志编委等职位。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_刘宏伟","group":"supervisoryCommittee","name":"刘宏伟","title":"监事","isMale":true,"age":"49","degree":"本科","salary":"158.0万","stockAmount":"-","description":"刘宏伟先生:1971年10月出生，本科学士学位。中国国籍,无境外永久居留权。1996年入职天士力,历任天津天士力医药营销集团有限公司销售代表、区域经理、大区经理、星火(县乡级市场)分公司总经理、广东天士力医药有限公司总经理、天津天士力医药营销集团医院板块总经理,现任天津天士力医药商业有限公司总经理、天士力医药集团股份有限公司副总经理、天津天士力医药营销集团股份有限公司监事会主席。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_章顺楠","group":"supervisoryCommittee","name":"章顺楠","title":"监事","isMale":true,"age":"47","degree":"硕士","salary":"99.68万","stockAmount":"-","description":"章顺楠先生:1973年11月出生,硕士毕业,正高级研究员,注册执业药师。曾任天士力药物研究所研究员、所长助理,天士力制药股份有限公司技术研究部经理、技术总监。现任天士力医药集团股份有限公司副总经理,兼任天士力医药集团制剂技术中心主任、国际产业中心技术负责人、现代中药先进制造技术国家地方联合工程实验室技术带头人、创新中药关键技术国家重点实验室学术带头人、天津市现代中药先进制造“131”创新型人才团队负责人、中国药科大学硕士生导师、天津中医药大学专业硕士生导师、中华中医药学会制药工程分会委员、中国中药协会中药质量与安全专委会委员。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_蔡金勇","group":"supervisoryCommittee","name":"蔡金勇","title":"职工监事","isMale":true,"age":"48","degree":"硕士","salary":"111.5万","stockAmount":"-","description":"蔡金勇先生简历:性别男,1972年8月11日出生,民族汉,硕士,中共党员,2001年4月毕业于南开大学工商管理硕士专业,2001年5月至今在天士力制药集团股份有限公司工作。","lastUpdated":"2018-04-10"},{"id":"天士力医药集团股份有限公司_鞠爱春","group":"supervisoryCommittee","name":"鞠爱春","title":"职工监事","isMale":true,"age":"47","degree":"本科","salary":"75.03万","stockAmount":"-","description":"鞠爱春先生简历:性别男,1973年1月11日出生,民族汉,学士,中共党员,1995年7月毕业于黑龙江中医药大学中医药专业,2005年1月至今在天士力制药集团股份有限公司子公司天津天士力之骄药业有限公司工作。","lastUpdated":"2018-04-10"},{"id":"天士力医药集团股份有限公司_朱永宏","group":"manager","name":"朱永宏","title":"总经理","isMale":true,"age":"55","degree":"博士","salary":"284.7万","stockAmount":"-","description":"朱永宏先生:1965年1月出生,博士、工商管理硕士,研究员,注册执业药师,国务院特殊津贴专家。曾任天津天士力制药集团有限公司市场营销部部长,天津天士力集团有限公司总裁助理兼天士力广告有限公司总经理,天津天士力集团有限公司总裁特别助理兼天津天士力国际公司总经理,天津天士力集团有限公司董事长助理兼研究院副院长,天士力控股集团有限公司副总裁兼生产制造事业群首席执行官。现任天士力制药集团股份有限公司副董事长、总经理,兼任中国医药创新促进会副秘书长、天津滨海高新技术产业开发区科学技术协会副会长、天津市人民对外友好协会理事、天津市北辰区工商业联合会副主席等职务。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_于杰","group":"manager","name":"于杰","title":"董事会秘书","isMale":true,"age":"45","degree":"硕士","salary":"163.4万","stockAmount":"-","description":"于杰先生,男,1975年出生,管理学硕士。自2001年毕业后至2014年,先后在华为技术有限公司产品行销、市场品牌和公共事务等领域工作,曾任华为公司品牌规划管理部部长、中国媒体事务部部长等职务,主导过华为市场管理流程变革、全球品牌策略和重大外部沟通等项目。2015年初加入中国民生投资股份有限公司集团董事局,担任品牌管理办公室主任,主导投资集团及其下属被投公司的品牌体系管理工作。2016年底加入天士力医药集团股份有限公司,2017年3月26日起,任公司副总经理兼董事会秘书。","lastUpdated":"2018-04-17"},{"id":"天士力医药集团股份有限公司_魏洁","group":"manager","name":"魏洁","title":"财务总监","isMale":false,"age":"43","degree":"本科","salary":"99.20万","stockAmount":"-","description":"魏洁,女,1977年出生,2001年毕业于天津工业大学管理学院财会系,管理学学士,中级会计师,美国注册管理会计师(CMA)。2002年加入天士力以来从预算管理岗位做起,天士力医药集团股份有限公司管理会计部财务经理、子公司天津天士力现代中药有限公司财务经理、公司财务总监助理与财务副总监等职务。","lastUpdated":"2018-07-11"}],"companyName":"天士力医药集团股份有限公司","province":"天津市","englishName":"Tasly Pharmaceutical Group Co Ltd","industry":"医药生物 — 中药Ⅱ","website":"www.tasly.com","mainBusiness":"软胶囊剂、滴丸剂、颗粒剂、硬胶囊剂、片剂、丸剂的生产及销售","productsName":["复方丹参滴丸","养血清脑颗粒","注射用益气复脉（冻干）","藿香正气滴丸","蒂清","水林佳"],"actualController":"闫凯境、闫希军、吴迺峰、李畇慧","actualControllerSharePercentage":"11.83、7.81、3.74、1.01%","registeredCapital":"15.13亿元","employeeAmount":"9235","phone":"86-022-26736999;86-022-26735302","location":"天津市北辰区普济河东道2号(天士力现代中药城)","chineseDescription":"天士力医药集团股份有限公司是以制药业为中心的高科技企业,是天津市重点支持的大企业集团之一,主营现代中药、化学药等的科研、种植、提取、销售等。公司自行研制成功具有国际先进水平的大型自动化滴丸生产线,主导产品复方丹参滴丸以药品身份进入韩国、越南等国家和地区的医药市场,在马来西亚、南非等国家地区建立公司,形成了多层次的营销体系。公司荣获了“中国制药集团研发 20 强”、“中国医药工业百强”等荣誉奖项。","foundedDate":"1998-04-30","goPublicDate":"2002-08-23","companyHistory":"天士力医药集团股份有限公司原名天士力制药集团股份有限公司。\n　　天士力制药集团股份有限公司（以下简称公司或本公司）系经天津市人民政府津股批〔2000〕4号文批准，由天士力控股集团有限公司等单位发起设立，于2000年4月30日在天津市工商行政管理局登记注册，总部位于天津市。公司现持有统一社会信用代码为9112000023944464XD的营业执照，注册资本1,080,475,878.00元，股份总数1,080,475,878股（每股面值1元），有限售条件的流通股份A股47,633,224股；无限售条件的流通股份A股1,032,842,654股。公司股票已于2002年8月23日在上海证券交易所挂牌交易。收起▲","shareholders":[{"organizationId":"00059682","holderName":"天士力控股集团有限公司","totalShare":"6.83亿","sharePercentage":"45.18%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"4476.51万","sharePercentage":"2.96%"},{"organizationId":"T000189615","holderName":"天津和悦科技发展合伙企业(有限合伙)","totalShare":"2917.54万","sharePercentage":"1.93%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"2804.94万","sharePercentage":"1.85%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1390.05万","sharePercentage":"0.92%"},{"organizationId":"T000189616","holderName":"天津康顺科技发展合伙企业(有限合伙)","totalShare":"1250.37万","sharePercentage":"0.83%"},{"organizationId":"","holderName":"大成基金-农业银行-大成中证金融资产管理计划","totalShare":"859.24万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"嘉实基金-农业银行-嘉实中证金融资产管理计划","totalShare":"859.24万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"银华基金-农业银行-银华中证金融资产管理计划","totalShare":"859.24万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"工银瑞信基金-农业银行-工银瑞信中证金融资产管理计划","totalShare":"859.24万","sharePercentage":"0.57%"}],"englishDescription":"TASLY PHARMACEUTICAL GROUP CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical products. The Company provides traditional Chinese medicines, chemical preparations, chemical raw materials and biological drugs. The Company's products are applied in the treatment of cardiovascular and cerebrovascular diseases, tumours, cat fever and hepatopathy, among others. Its products include Danshen dripping pills, nourishing blood and cleaning brain granules, bupleurum pills, pills for stomach diseases and andrographolide pills, among others. In addition, the Company is also engaged in pharmaceutical trading business.","englishIndustry":"Major Drugs","Price to earnings (ttm)":"30.80","Price to sales (ttm)":"1.43","Price to book (mrq)":"2.30","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"78.72","Lt debt to equity (mrq)":"29.20","Return on investment (ttm)":"5.41","Return on equity (ttm)":"3.44","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"21,432.58","Cash payments":"(14,302.02)","Cash taxes paid":"(1,255.21)","Changes in working capital":"(4,195.19)","Cash from operating activities":"1,680.15","Capital expenditures":"(730.78)","Other investing cash flow items, total":"237.79","Cash from investing activities":"(492.98)","Financing cash flow items":"59.04","Total cash dividends paid":"(903.58)","Issuance (retirement) of debt, net":"(1,544.96)","Cash from financing activities":"(2,389.51)","Foreign exchange effects":"3.85","Net change in cash":"(1,198.50)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"17.34","52 Week High":"19.44","52 Week Low":"13.33","Pricing date":"","10 Day Average Trading Volume":"21.57","Market Capitalization":"26,229.63","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"470.22","Beta":"0.90","1 Day Price Change":"0.70","13 Week Price Return (Daily)":"23.77","26 Week Price Return (Daily)":"10.73","5 Day Price Return (Daily)":"6.18","52 Week Price Return (Daily)":"7.37","Year To Date Price Return (Daily)":"12.45","Month to Date Price Return (Daily)":"6.91","Price Relative to S&P500 (4 Week)":"-3.86","Price Relative to S&P500 (13 Week)":"6.95","Price Relative to S&P500 (26 Week)":"-0.43","Price Relative to S&P500 (52 Week)":"-5.65","Price Relative to S&P500 (YTD)":"3.62"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.66","EPS excl. Extra Items (TTM)":"0.56","EPS Normalized (Annual)":"0.67","Revenue per Share (Annual)":"12.56","Revenue per Share (TTM)":"12.18","Book Value (Per Share Annual)":"7.36","Book Value (Per Share Quarterly)":"7.56","Tangible Book Value (Per Share Annual)":"6.07","Tangible Book Value (Per Share Quarterly)":"6.26","Cash Per Share (Per Share Annual)":"1.04","Cash Per Share (Per Share Quarterly)":"1.63","Cash Flow (Per Share Annual)":"0.92","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.33","Dividends (Per Share TTM)":"0.33","EBITD (Per Share TTM)":"1.16","EPS Basic excl. Extra Items (Annual)":"0.66","EPS Basic excl. Extra Items (TTM)":"0.56","EPS incl. Extra Items (Annual)":"0.66","EPS incl. Extra Items (TTM)":"0.56","Free Cash Flow (Per Share TTM)":"-0.09","Dividend (Per Share 5Y)":"0.32"},"Valuation":{"P/E excl. Extra Items (Annual)":"26.19","P/E excl. Extra Items (TTM)":"30.80","P/E Normalized (Annual)":"25.72","Price to sales (Annual)":"1.38","Price to sales (TTM)":"1.43","Price to Tangible Book (Annual)":"2.86","Price to Tangible Book (Quarterly)":"2.77","Price to Free Cash Flow (Per Share Annual)":"572.82","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"2.36","Price to Book (Quarterly)":"2.30","P/E Basic excl. Extra Items (TTM)":"24.55","P/E excl. Extra Items High (TTM)":"38.11","P/E excl. Extra Items Low (TTM)":"16.46","P/E incl. Extra Items (TTM)":"30.80","Net Debt (Interim)":"6,530.65","Net Debt (Annual)":"7,307.13","Dividend Yield (5Y)":"1.36","Dividend Yield":"1.90","Current Dividend Yield (TTM)":"1.90"},"Financial Strength":{"Free Cash Flow (Annual)":"45.79","Current Ratio (Annual)":"1.91","Net Interest coverage (Annual)":"3.26","Long Term Debt/Equity (Annual)":"29.04","Payout Ratio (Annual)":"50.98","Quick Ratio (Annual)":"1.62","Total Debt/Total Equity (Annual)":"79.82","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.99","Long Term Debt/Equity (Quarterly)":"29.20","Quick Ratio (Quarterly)":"1.70","Total Debt/Total Equity (Quarterly)":"78.72","Free Cash Flow (TTM)":"-134.15","Net Interest Coverage (TTM)":"2.97","Payout Ratio (TTM)":"60.19"},"Margins":{"Gross Margin (Annual)":"31.28","Gross Margin (TTM)":"29.77","Net Profit Margin % (Annual)":"5.28","Net Profit Margin (TTM)":"4.59","Operating Margin (Annual)":"7.03","Operating Margin (TTM)":"6.29","Pretax Margin (TTM)":"6.21","Pretax Margin (Annual)":"7.00","Operating Margin (5Y)":"10.26","Pretax Margin (5Y)":"10.36","Free Operating Cash Flow/Revenue (5Y)":"-4.18","Free Operating Cash Flow/Revenue (TTM)":"-0.73","Gross Margin (5Y)":"35.50","Net Profit Margin (5Y)":"8.40"},"Management Effectiveness":{"Return on Assets (Annual)":"4.08","Return on Equity (TTM)":"3.44","Return on Average Equity (Annual)":"9.25","Return on Average equity (TTM)":"7.56","Return on Investment (Annual)":"6.56","Return on Investment (TTM)":"5.41","Return on Average Assets (5Y)":"6.90","Return on Average Equity (5Y)":"15.44","Return on Investment (5Y)":"12.61","Asset Turnover (Annual)":"0.77","Asset Turnover (TTM)":"0.75","Inventory Turnover (Annual)":"5.28","Inventory Turnover (TTM)":"5.31","Net Income/Employee (Annual)":"108,397.80","Net Income/Employee (TTM)":"91,274.48","Receivables Turnover (Annual)":"2.27","Receivables Turnover (TTM)":"2.07","Revenue/Employee (Annual)":"2,052,873.00","Revenue/Employee (TTM)":"1,990,227.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-13.53","Revenue Growth Rate (5Y)":"8.60","EPS Growth (Quarterly YoY)":"-34.02","EPS Growth (TTM YoY)":"-47.49","EPS Growth Rate (5Y)":"-6.90","Dividend Growth Rate (3Y)":"-6.21","Revenue Growth (TTM YoY)":"-1.23","Revenue Growth (Per Share 5Y)":"7.62","Revenue Growth Rate (3Y)":"10.86","EPS Growth Rate (3Y)":"-5.23","Book Value Growth Rate (Per Share 5Y)":"17.07","Tangible Book Value Total Equity CAGR (5Y)":"17.96","Capital Spending growth rate 5 year":"-0.65","EBITDA CAGR (5Y)":"0.86","EBITDA Interim CAGR (5Y)":"-2.72","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"9.57","Net Profit Margin Growth Rate (5Y)":"-14.46"},"Income Statement":{"Revenue (Annual)":"18,998.31","Revenue (TTM)":"18,379.75","EBITD (Annual)":"2,350.22","EBITD (TTM)":"1,743.79","Earnings Before Taxes (Annual)":"1,330.80","Earnings Before Taxes (TTM)":"1,140.81","Net Income to Common (Annual)":"1,001.43","Net Income to Common (TTM)":"848.10","Earnings Before Taxes Normalized (Annual)":"1,355.26","Net Income Available to Common Normalized (Annual)":"1,019.86","Diluted Normalized EPS excl. Extra Items (TTM)":"0.56"}}}